

---

**THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION**

---

**If you are in any doubt** as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

**If you have sold** all your shares in China Resources Pharmaceutical Group Limited, you should at once hand this circular and the accompanying form of proxy to the purchaser or to the bank, stockbroker or other agent through whom the sale was effected for transmission to the purchaser.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

---



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

**PROPOSALS FOR GENERAL MANDATES TO BUY BACK SHARES  
AND TO ISSUE SHARES,  
RE-ELECTION OF RETIRING DIRECTORS,  
APPOINTMENT OF AUDITOR  
AND NOTICE OF ANNUAL GENERAL MEETING**

---

The notice convening the Annual General Meeting of China Resources Pharmaceutical Group Limited to be held at 50th Floor, China Resources Building, 26 Harbour Road, Wanchai, Hong Kong on Friday, 12 June 2026 at 3:30 p.m. is set out on pages 19 to 23 of this circular. Shareholders are advised to complete and return the accompanying proxy form in accordance with the instructions printed thereon as soon as possible and in any event not less than 48 hours before the time appointed for holding the Annual General Meeting or any adjournment thereof. Completion and return of the proxy form will not preclude you from attending and voting at the Annual General Meeting if you so wish.

If a Typhoon Signal No. 8 or above is hoisted, or a Black Rainstorm Warning Signal or “extreme conditions after super typhoons” announced by the HKSAR Government is/are in force on the date of the Annual General Meeting, the Annual General Meeting will be considered to be postponed or adjourned. The Company will post an announcement on the Company’s website ([www.crpharm.com](http://www.crpharm.com)) and the Stock Exchange’s website ([www.hkexnews.hk](http://www.hkexnews.hk)) to notify Shareholders if there are any changes on the date, time and place of the Annual General Meeting.

The Annual General Meeting will be held as scheduled when an Amber or a Red Rainstorm Warning Signal is in force. Shareholders should decide on their own whether they would attend the Annual General Meeting under bad weather conditions bearing in mind their own situations.

19 May 2026

---

## DEFINITIONS

---

*In this circular, the following expressions have the following meanings unless the context requires otherwise:*

“Annual General Meeting”	the annual general meeting of the Company to be held at 50th Floor, China Resources Building, 26 Harbour Road, Wanchai, Hong Kong on Friday, 12 June 2026 at 3:30 p.m., notice of which is set out on pages 19 to 23 of this circular
“Articles of Association”	the articles of association of the Company currently effective as of the date of this circular
“Board”	the board of Directors
“Board Diversity Policy”	Board diversity policy of the Company
“Buy-back Proposal”	the proposal to give a general mandate to the Directors to exercise the powers of the Company to buy back Shares during the period as set out in the Buy-back Resolution up to a maximum of 10% of the issued Shares (excluding treasury shares, if any) at the date of the Buy-back Resolution
“Buy-back Resolution”	the ordinary resolution proposed under item No. 6 of the notice of the Annual General Meeting
“CCASS”	Central Clearing and Settlement System, a securities settlement system used within the Hong Kong Exchanges and Clearing Limited market system
“China” or “PRC”	the People’s Republic of China, excluding, for the purposes of this circular only, Hong Kong, Macau Special Administrative Region of the PRC and Taiwan
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (as amended from time to time)
“Company”	China Resources Pharmaceutical Group Limited, a company incorporated in Hong Kong with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange (stock code: 3320)
“controlling shareholder”	has the meaning ascribed to it under the Listing Rules

---

## DEFINITIONS

---

“CRC”	China Resources Company Limited (中國華潤有限公司), a company established in the PRC with limited liability and a state-owned enterprise under the supervision of the State-owned Assets Supervision and Administration Commission of the State Council in the PRC and is the ultimate holding company of the Company
“CR Double-Crane”	China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司), a company incorporated under the laws of the PRC, the shares of which are listed on the Shanghai Stock Exchange (stock code: 600062) and a non-wholly-owned subsidiary of the Company
“CR Holdings”	China Resources (Holdings) Company Limited, a company incorporated in Hong Kong with limited liability and a controlling Shareholder and is ultimately owned by CRC
“CR Jiangzhong”	China Resources Jiangzhong Pharmaceutical Co., Ltd. (華潤江中藥業股份有限公司), formerly known as Jiangzhong Pharmaceutical Co., Ltd (江中藥業股份有限公司), a company established in the PRC, the shares of which are listed on the Shanghai Stock Exchange (stock code: 600750) and a non-wholly-owned subsidiary of the Company
“CR Sanjiu”	China Resources Sanjiu Medical & Pharmaceutical Company Limited (華潤三九醫藥股份有限公司), a company incorporated under the laws of the PRC, the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000999) and a non-wholly-owned subsidiary of the Company
“Directors”	the directors of the Company
“Dong-E-E-Jiao”	Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司), a company incorporated under the laws of the PRC, the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000423) and a non-wholly-owned subsidiary of the Company
“Group”	the Company and its subsidiaries
“HKSCC”	Hong Kong Securities Clearing Company Limited
“HK\$”	Hong Kong dollar(s), the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC

---

## DEFINITIONS

---

“Latest Practicable Date”	8 May 2026, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange (as amended from time to time)
“Nomination Committee”	the nomination committee of the Company
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (as amended from time to time)
“Share(s)”	share(s) of the Company
“Shareholder(s)”	shareholders of the Company
“Share Buy-back Rules”	the relevant rules set out in the Listing Rules to regulate the buy-back or purchase by companies with primary listings on the Stock Exchange of their own securities on the Stock Exchange
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiaries”	has the meaning ascribed to it under the Listing Rules
“Takeovers Code”	the Hong Kong Code on Takeovers and Mergers (as amended from time to time)
“treasury shares”	has the meaning ascribed to it under the Listing Rules

*Note:* For ease of reference, the names of PRC established companies or entities have been included in this circular in both Chinese and English languages, and in the event of any inconsistency, the Chinese version shall prevail.



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

*Directors:*

*Chairman and Executive Director*

Bai Xiaosong

*Executive Directors*

Cheng Jie

Liu Changan

*Non-executive Directors*

Guo Wei

Sun Yongqiang

Wang Yuhang

Guo Chuan

Jiao Ruifang

*Independent non-executive Directors*

Chiu Mun Wai

Fu Tingmei

Zhang Kejian

Shi Luwen

*Registered Office:*

41/F,

China Resources Building

26 Harbour Road, Wanchai

Hong Kong

19 May 2026

*To the Shareholders*

Dear Sirs or Madams,

**PROPOSALS FOR GENERAL MANDATES TO BUY BACK SHARES  
AND TO ISSUE SHARES,  
RE-ELECTION OF RETIRING DIRECTORS,  
APPOINTMENT OF AUDITOR  
AND NOTICE OF ANNUAL GENERAL MEETING**

**INTRODUCTION**

The purpose of this circular is to seek your approval as set out in the notice of Annual General Meeting of the relevant ordinary resolutions to be proposed at the Annual General Meeting and to provide you with information regarding the general mandates to buy back Shares and to issue Shares, re-election of retiring Directors and appointment of auditor.

---

## LETTER FROM THE BOARD

---

### GENERAL MANDATE TO BUY BACK SHARES

At the annual general meeting of the Company held on 23 May 2025, a general mandate was given to the Directors to exercise the powers of the Company to buy back Shares. Such mandate will lapse at the conclusion of the Annual General Meeting. It is therefore proposed to seek your approval of the Buy-back Resolution at the Annual General Meeting to give a fresh general mandate to the Directors to exercise the powers of the Company to buy back Shares. An explanatory statement as required under the Share Buy-back Rules to provide the requisite information of the Buy-back Proposal is set out in Appendix I to this circular.

### GENERAL MANDATE TO ISSUE SHARES

At the annual general meeting of the Company held on 23 May 2025, a general mandate was given to the Directors to issue Shares. Such mandate will lapse at the conclusion of the Annual General Meeting. It is therefore proposed at the Annual General Meeting two ordinary resolutions respectively granting to the Directors a general mandate to allot, issue and deal with Shares (including any sale or transfer of treasury shares of the Company) not exceeding 20% of the issued Shares (excluding treasury shares, if any) at the date of the resolution (i.e. not exceeding 1,256,502,092 Shares based on 6,282,510,461 Shares in issue as at the Latest Practicable Date and assuming that such issued Shares remain the same at the date of passing the resolution) and adding to such general mandate so granted to the Directors any Shares representing the total number of the Shares bought back by the Company after the granting of the general mandate to buy back up to 10% of the issued Shares (excluding treasury shares, if any) at the date of the Buy-back Resolution.

### RE-ELECTION OF RETIRING DIRECTORS

As at the Latest Practicable Date, the Board comprises Mr. Bai Xiaosong as the chairman of the Board and executive Director; Mr. Cheng Jie and Mr. Liu Changan as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors; Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.

Pursuant to Article 78 of the Articles of Association, Mr. Cheng Jie, Mr. Liu Changan and Mr. Wang Yuhang will retire from office at the Annual General Meeting and, being eligible, will offer themselves for re-election.

Pursuant to Article 88 of the Articles of Association, Mr. Bai Xiaosong, Mr. Sun Yongqiang, Mdm. Jiao Ruifang and Mr. Shi Luwen (“**Mr. Shi**”) will retire from office by rotation at the Annual General Meeting and, being eligible, will offer themselves for re-election.

---

## LETTER FROM THE BOARD

---

The Nomination Committee has identified candidates pursuant to criteria set out in the Board Diversity Policy and the nomination policy adopted by the Company and assessed and reviewed the independence confirmation given by Mr. Shi to the Company based on the independence criteria as set out in Rule 3.13 of the Listing Rules. Mr. Shi is and was not connected with any Directors, senior management of the Company or substantial or controlling Shareholders. The Board is also not aware of any circumstance that might influence Mr. Shi in exercising independent judgment, and is satisfied that Mr. Shi has the required character, integrity, independence and experience to fulfill the role of an independent non-executive Director and Mr. Shi will be able to provide impartial judgment and maintain an independent view of the Group's affairs. The Board considers Mr. Shi to be independent. The Board is of the view that Mr. Shi is beneficial to the Board with the diversity of his professional experience that contributes to invaluable expertise, continuity and stability to the Board and the Company has benefited greatly from his contribution and valuable insights derived from his in-depth knowledge of the Company. The Board believes that Mr. Shi will continue to contribute effectively to the Board.

Details of the retiring Directors proposed to be re-elected at the Annual General Meeting are set out in Appendix II to this circular.

### APPOINTMENT OF AUDITOR

KPMG will retire as the auditor of the Company with effect from the close of the Annual General Meeting and, being eligible, offer itself for appointment.

The Board, upon the recommendation of the audit committee of the Company, proposed to appoint KPMG as the auditor for the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorise the Board to fix their remuneration for the year ending 31 December 2026. Having considered factors including, among others, the business and the expected growth of the Group, the expected audit scope, the audit timetable and the auditor's resources, the auditor's fees for audit services are expected to be not less than RMB34 million.

### ANNUAL GENERAL MEETING

Set out on pages 19 to 23 of this circular is the notice convening the Annual General Meeting.

Reference is made to the annual results announcement dated 25 March 2026 for the year ended 31 December 2025 (the "**Annual Results Announcement**") and the annual report dated 28 April 2026 for the year ended 31 December 2025 (the "**Annual Report**").

Due to administrative reasons, the Annual General Meeting, which was originally scheduled to be held on Friday, 29 May 2026 as set out in the Annual Results Announcement and the Annual Report, will be postponed to Friday, 12 June 2026 as set out in this circular.

---

## LETTER FROM THE BOARD

---

In this respect, the original book closure dates for the purpose of ascertaining Shareholders' right to attend and vote at the Annual General Meeting and for ascertaining Shareholders' entitlement (subject to Shareholders' approval at the Annual General Meeting) to the proposed final dividend for the year ended 31 December 2025 as set out in the Annual Results Announcement and the Annual Report are revised as follows:

For ascertaining Shareholders' right to attend and vote at the Annual General Meeting:

	<b>Original</b>	<b>Revised</b>
Latest time to lodge transfers in order to be entitled to attend and vote at the Annual General Meeting	4:30 p.m. on Friday, 22 May 2026	4:30 p.m. on Monday, 8 June 2026
Closure dates of register of members (both days inclusive)	Tuesday, 26 May 2026 to Friday, 29 May 2026	Tuesday, 9 June 2026 to Friday, 12 June 2026
Record date	Friday, 29 May 2026	Friday, 12 June 2026
Annual General Meeting	Friday, 29 May 2026	Friday, 12 June 2026

For ascertaining Shareholders' entitlement (subject to Shareholders' approval at the Annual General Meeting) to the proposed final dividend:

	<b>Original</b>	<b>Revised</b>
Latest time to lodge transfers in order to be entitled to the proposed final dividend	4:30 p.m. on Thursday, 4 June 2026	4:30 p.m. on Thursday, 18 June 2026
Closure dates of register of members (both days inclusive)	Friday, 5 June 2026 to Monday, 8 June 2026	Monday, 22 June 2026 to Tuesday, 23 June 2026
Record date	Monday, 8 June 2026	Tuesday, 23 June 2026
Latest time to lodge dividend currency election form	4:30 p.m. on Thursday, 2 July 2026	4:30 p.m. on Thursday, 16 July 2026
Proposed final dividend payment date	Tuesday, 21 July 2026	Monday, 3 August 2026

During the revised periods of the closure of register of members, no share transfers will be registered. For registration, all share transfer documents accompanied by the relevant share certificates must be lodged with the Company's share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong before the relevant latest time to lodge transfers.

Save for the changes as stated above, all other information and contents as set out in the Annual Results Announcement and the Annual Report shall remain unchanged.

---

## LETTER FROM THE BOARD

---

At the Annual General Meeting, resolutions will be proposed to the Shareholders, including re-election of retiring Directors, the Buy-back Proposal, the general mandate for Directors to issue new Shares and the extension of the general mandate to issue new Shares.

### **ACTION TO BE TAKEN**

A proxy form for use at the Annual General Meeting is enclosed with this circular. Shareholders are advised to read the notice contained herein and to complete and return the accompanying proxy form in accordance with the instructions printed thereon as soon as possible and in any event not less than 48 hours before the time appointed for holding the Annual General Meeting or any adjournment thereof. Completion and return of the proxy form will not preclude you from attending and voting at the Annual General Meeting if you so wish.

### **VOTING BY WAY OF POLL**

Pursuant to Rule 13.39(4) of the Listing Rules, all votes at the Annual General Meeting shall be taken by poll except where the chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. The Company will announce the results of the poll in the manner prescribed under Rules 13.39(5) and 13.39(5A) of the Listing Rules.

### **RECOMMENDATION**

The Directors believe that the Buy-back Proposal, the proposed general mandate for Directors to issue new Shares, the proposed extension of the general mandate to issue new Shares, the proposed re-election of retiring Directors and the proposed appointment of auditor are all in the best interests of the Company and Shareholders. Accordingly, the Directors recommend that all Shareholders should vote in favour of such resolutions to be proposed at the Annual General Meeting.

Yours faithfully,  
**China Resources Pharmaceutical Group Limited**  
**Bai Xiaosong**  
*Chairman*

*This appendix serves as an explanatory statement, as required by the Share Buy-back Rules, to provide requisite information to you for your consideration of the proposal to permit the buy-back of Shares up to a maximum of 10% of the issued Shares (excluding treasury shares, if any) as at the date of the Buy-back Resolution.*

*This appendix also constitutes a memorandum as required under section 239(2) of the Companies Ordinance.*

## **1. ISSUED SHARES**

As at the Latest Practicable Date, the number of issued Shares (excluding treasury shares, if any) is 6,282,510,461 Shares. As at the Latest Practicable Date, the Company did not hold any treasury shares.

Subject to the passing of the Buy-back Resolution and on the basis that no further Shares will be issued or bought back prior to the Annual General Meeting, the Company would be allowed under the Buy-back Proposal to buy back a maximum of 628,251,046 Shares representing not more than 10% of the issued Shares (excluding treasury shares, if any) as at the Latest Practicable Date.

## **2. REASONS FOR BUY-BACK**

The Directors believe that the Buy-back Proposal is in the best interest of the Company and Shareholders. Such buy-back may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net assets and/or earnings per Share of the Company and will only be made when the Directors believe that such a buy-back will benefit the Company and Shareholders. On the other hand, Shares repurchased by the Company and held as treasury shares may provide more flexibility to the Board to resell the treasury shares on the market to raise additional funds for the Company, or transfer or use for share grants under share schemes that comply with Chapter 17 of the Listing Rules and for other purposes permitted under the Listing Rules, the Articles of Association and the Companies Ordinance.

## **3. FUNDING OF BUY-BACK**

For the purpose of buy-back of Shares, the Company may only apply funds legally available for such purpose in accordance with the Articles of Association and the Companies Ordinance. The Companies Ordinance provides that payment in respect of a share buy-back may be made out of the Company's distributable profits and/or out of the proceeds of a fresh issue of Shares made for the purpose of the buy-back.

There might be an adverse impact on the working capital or gearing position of the Company as compared with the position disclosed in the audited accounts contained in the annual report for the year ended 31 December 2025 in the event that the power to buy back Shares pursuant to the Buy-back Proposal was to be carried out in full at any time during the proposed buy-back period. However, the Directors do not propose to exercise the power to buy back Shares pursuant to the Buy-back Proposal to such extent as would, in the circumstances,

have a material adverse effect on the working capital requirements of the Company or the gearing levels which in the opinion of the Directors are from time to time appropriate for the Company.

#### 4. SHARE PRICES

The highest and lowest prices at which the Shares have traded on the Stock Exchange during each of the previous twelve months before the Latest Practicable Date were as follows:

	Trading price per Share	
	Highest <i>HK\$</i>	Lowest <i>HK\$</i>
May 2025	5.21	4.86
June 2025	5.47	4.90
July 2025	5.76	5.14
August 2025	5.55	4.85
September 2025	5.03	4.71
October 2025	5.01	4.73
November 2025	5.05	4.67
December 2025	4.85	4.35
January 2026	4.68	4.43
February 2026	4.71	4.41
March 2026	5.82	4.34
April 2026	6.53	5.15
May 2026 (up to and including the Latest Practicable Date)	5.28	4.98

#### 5. GENERAL

The Directors will exercise the powers of the Company to make buy-backs pursuant to the Buy-back Resolution and in accordance with the Listing Rules and the applicable laws of Hong Kong.

None of the Directors nor, to the best of their knowledge having made all reasonable enquiries, their close associates (as defined under the Listing Rules), have any present intention to sell any Shares to the Company or its subsidiaries under the Buy-back Proposal if such is approved by the Shareholders.

No core connected persons (as defined in the Listing Rules) have notified the Company that they have a present intention to sell Shares to the Company or its subsidiaries, or have undertaken not to do so, in the event that the Buy-back Proposal is approved by the Shareholders.

The Company may cancel such repurchased Shares or hold them as treasury shares, subject to market conditions and the Group's capital management needs at the relevant time of the repurchases, to the extent permitted by and in compliance with the requirements of the Listing Rules, the Companies Ordinance and other applicable laws, rules and regulations from time to time in force.

For any treasury shares deposited with CCASS pending resale on the Stock Exchange, the Company will adopt appropriate measures to ensure that it does not exercise any Shareholders' rights or receive any Shareholders' entitlements which would otherwise be suspended under the applicable laws if those shares were registered in the Company's own name as treasury shares. These measures include that the Company shall (i) procure its broker not to give any instructions to HKSCC to vote at general meetings of the Company for the treasury shares deposited with CCASS; and (ii) in the case of dividends or distributions, withdraw the treasury shares from CCASS, and either re-register them in its own name as treasury shares or cancel them, in each case before the record date for the dividends or distributions, or take any other measures.

The Company confirms that the explanatory statement set out in this Appendix contains the information required under Rule 10.06(1)(b) of the Listing Rules and that neither the explanatory statement nor the Buy-back Proposal has unusual features.

## **6. TAKEOVERS CODE**

If on the exercise of the power to buy back Shares pursuant to the Buy-back Proposal, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purposes of Rule 32 of the Takeovers Code.

As a result, a Shareholder or group of Shareholders acting in concert, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, CRC is interested in 3,354,786,612 Shares (representing approximately 53.40% voting rights in the total issued Shares (excluding treasury shares, if any) as at the Latest Practicable Date). In the event that the Directors exercise in full the power to buy back Shares under the Buy-back Proposal, then (if the present shareholding remains the same) the attributable interest of CRC would be increased to approximately 59.33% voting rights in the issued Shares (excluding treasury shares, if any).

The Directors are not aware of any consequences which may arise under the Takeovers Code as a result of any buy-backs made under the Buy-back Proposal. The Company has no present intention to buy back Shares to such extent as to result in the number of Shares held by the public being reduced to less than 25%.

## **7. SHARES BUY-BACK MADE BY THE COMPANY**

The Company had not bought back any Shares (whether on the Stock Exchange or otherwise) in the six months preceding the Latest Practicable Date.

*The following are the particulars of the Directors proposed to be re-elected at the Annual General Meeting:*

**Mr. Bai Xiaosong** (*Executive Director and Chairman*)

Mr. Bai Xiaosong, aged 54, was appointed as an executive Director and Chief Executive Officer of the Company in January 2022. He resigned as Chief Executive Officer and was appointed as the chairman of the board and the chairman of the nomination committee of the Company in August 2024. Mr. Bai currently serves as a director of CR Sanjiu, CR Double-Crane and CR Jiangzhong. Mr. Bai served as a vice president of CR Sanjiu from June 2021 to December 2021. He served as an assistant general manager of China Resources Snow Breweries (China) Co., Ltd. (華潤雪花啤酒(中國)有限公司) (“**CR Snow Breweries**”) from March 2016 to October 2018 and served as a deputy general manager of CR Snow Breweries from October 2018 to June 2021. He also served as an associate president of CR Double-Crane, a human resources and development controller and a deputy general manager of China Resources Shenyang Sanyo Compressor Co., Ltd. (瀋陽華潤三洋壓縮機有限公司), a director of strategic management department of CR Holdings. Mr. Bai holds a bachelor’s degree in Engineering (Petroleum Processing) from Fushun Petroleum Institute, Department of Petrochemical Engineering and a master’s degree of Economics in Finance from Peking University, School of Economics.

Save as disclosed above, Mr. Bai (i) did not hold any directorship in other listed public companies in the last three years or any position with the Company or other members of the Group; and (ii) is and was not connected with any Directors, senior management or substantial or controlling shareholders of the Company.

There is no service contract between the Company and Mr. Bai for his position as executive Director. He has no fixed term of service with the Company. He will be subject to retirement by rotation and re-election at annual general meeting of the Company pursuant to the Articles of Association. Mr. Bai will not receive any Director’s emolument from the Company, and will receive a remuneration before tax of not less than RMB73,800 each month (plus incentive payments) from the Group by reference to his position and level of responsibilities, the remuneration policy of the Company and the prevailing market conditions.

As at the Latest Practicable Date, Mr. Bai beneficially owned 200,000 Shares within the meaning of Part XV of the SFO. Save as disclosed above, as at the Latest Practicable Date, Mr. Bai does not have any interest in the shares of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Bai has confirmed that there are no other matters relating to his re-election that need to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

**Mr. Cheng Jie** (*Executive Director and President*)

Mr. Cheng Jie, aged 47, has been appointed as an executive Director, the President and a member of each of the Executive Committee and Corporate Governance Committee on 26 August 2025. He is currently the director of certain subsidiaries of the Company. He has been serving as the chairman of Dong-E-E-Jiao since October 2024. He served as the 999 Ganmaoling product manager and product director, OTC sales and marketing director, deputy general manager of marketing center, and general manager of professional brands division of CR Sanjiu from July 2003 to January 2022. He has also served as the executive director of Aino (China) Pharmaceutical Co., Ltd. (澳諾(中國)製藥有限公司) from December 2019 to January 2022, director and general manager of Sanjiu Sanofi (Shenzhen) Health Industry Co., Ltd (三九賽諾菲(深圳)健康產業有限公司) from January 2017 to January 2022, and the president of Dong-E-E-Jiao from January 2022 to September 2024. Mr. Cheng was awarded the title of National Model Worker in 2025, Taishan Industrial Leadership Talent (Business Management Category) in 2023, Shandong Province Model Worker in 2023, etc. Mr. Cheng graduated from Shenyang Pharmaceutical University in the PRC in July 2003 with a Bachelor's degree in Science. He holds the title of senior engineer.

Save as disclosed above, Mr. Cheng (i) did not hold any directorship in other listed public companies in the last three years or any position with the Company or other members of the Group; and (ii) is and was not connected with any Directors, senior management or substantial or controlling shareholders of the Company.

There is no service contract between the Company and Mr. Cheng for his position as executive Director. He has no fixed term of service with the Company. He will be subject to retirement by rotation and re-election at annual general meeting of the Company pursuant to the Articles of Association. Mr. Cheng will not receive any Director's emolument from the Company, and is entitled to pre-tax basic monthly salary of RMB69,100 from the Company based on his position, duties and responsibilities as well as discretionary bonus and term-wide incentives based on the results performance of the Company and himself.

As at the Latest Practicable Date, Mr. Cheng does not have any interest in the shares of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Cheng has confirmed that there are no other matters relating to his re-election that need to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

**Mr. Liu Changan** (*Executive Director*)

Mr. Liu Changan, aged 53, has been appointed as an executive Director and a member of the Executive Committee on 18 September 2025. He has been a director of China Resources Pharmaceutical Holdings Company Limited, a subsidiary of the Company, since October 2024. Mr. Liu served in the Agricultural Committee and Agricultural Bureau of the Beijing Municipal Party Committee from January 2023 to July 2023. Mr. Liu graduated from the National Defense University of the People's Liberation Army in January 2004 with a Master's degree.

Save as disclosed above, Mr. Liu (i) did not hold any directorship in other listed public companies in the last three years or any position with the Company or other members of the Group; and (ii) is and was not connected with any Directors, senior management or substantial or controlling shareholders of the Company.

There is no service contract between the Company and Mr. Liu for his position as executive Director. He has no fixed term of service with the Company. He will be subject to retirement by rotation and re-election at annual general meeting of the Company pursuant to the Articles of Association. Mr. Liu will not receive any Director's emolument from the Company, and is entitled to pre-tax basic monthly salary of RMB60,600 from the Company based on his position, duties and responsibilities as well as discretionary bonus and term-wide incentives based on the results performance of the Company and himself.

As at the Latest Practicable Date, Mr. Liu does not have any interest in the shares of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Liu has confirmed that there are no other matters relating to his re-election that need to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

**Mr. Sun Yongqiang** (*Non-executive Director*)

Mr. Sun Yongqiang, aged 55, has been appointed as a non-executive Director and a member of the Remuneration and Appraisal Committee on 27 December 2023. He currently serves as a designated external director of business units of CR Holdings and has been appointed as a non-executive director of Konka Group Co., Ltd (康佳集團股份有限公司) (the shares of which are listed on the Shenzhen Stock Exchange, stock codes: 000016 and 200016) since August 2025. Mr. Sun was a non-executive director of China Resources Beverage (Holdings) Company Limited (listed on the Stock Exchange, stock code: 2460) from April 2024 to August 2025. Mr. Sun joined China Resources Group in 1998, from 2011 to 2023, he successively served as vice president, chief human resources officer and human resources director of China Resources Land Limited (“**CR Land**”, the shares of which are listed on the Stock Exchange, stock code: 1109) and also served as general manager and deputy general manager of China Resources Land (Hunan) Co., Ltd (華潤置地(湖南)有限公司, a subsidiary of CR Land). Mr. Sun holds a Bachelor's Degree in Engineering from Dalian University of Technology (大連理工大學).

Save as disclosed above, Mr. Sun (i) did not hold any directorship in other listed public companies in the last three years or any position with the Company or other members of the Group; and (ii) is and was not connected with any Directors, senior management or substantial or controlling shareholders of the Company.

There is no service contract between the Company and Mr. Sun for his position as a non-executive Director. He has no fixed term of service with the Company. He will be subject to retirement by rotation and re-election at annual general meeting of the Company pursuant to the Articles of Association. Mr. Sun will not receive any Director's emolument from the Company.

As at the Latest Practicable Date, Mr. Sun is interested in 38,000 shares of China Resources Beer (Holdings) Company Limited (an associated corporation of the Company and listed on the Main Board of the Stock Exchange, stock code: 291), and beneficially owned 30,000 shares of CR Land (an associated corporation of the Company), and 92,000 shares of China Resources Medical Holdings Company Limited (an associated corporation of the Company and listed on the Main Board of the Stock Exchange, stock code: 1515). Save as disclosed above, as at the Latest Practicable Date, Mr. Sun does not have any interest in the shares of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Sun has confirmed that there are no other matters relating to his re-election that need to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

**Mr. Wang Yuhang** (*Non-executive Director*)

Mr. Wang Yuhang, aged 53, is an external director of business units of CR Holdings. He was appointed as a non-executive Director of CR Land since June 2025. Mr. Wang served as the Vice President and Deputy General Manager of Environmental Health and Safety Department of China Resources Group from January 2015 to July 2024 and subsequently the Deputy General Manager of China Resources Chemical Innovative Materials Co., Ltd. from August 2024 to May 2025. Before joining China Resources Group, Mr. Wang served as the Deputy Director of Ionization Chamber of Beijing Department of Environmental Protection Radiation Environmental Research Center from April 1999 to May 2001; Manager of Consulting Department of Beijing Bona Baijia Cultural Development Co., Ltd from May 2001 to March 2002; the Deputy Director of Institute of Safety Management and Technology, Director of Registration Management Centre for Certified Safety Engineers and Director of Institute of Safety Production Theory and Regulatory Standards of China Academy of Safety Science and Technology during the periods from April 2002 to January 2009 and from August 2012 to January 2015; and Deputy Director of Security Office and General Manager of Safety and Environmental Department of China Agri-Industries Holdings Limited from January 2009 to August 2012.

Save as disclosed above, Mr. Wang (i) did not hold any directorship in other listed public companies in the last three years or any position with the Company or other members of the Group; and (ii) is and was not connected with any Directors, senior management or substantial or controlling shareholders of the Company.

There is no service contract between the Company and Mr. Wang for his position as a non-executive Director. He has no fixed term of service with the Company. He will be subject to retirement by rotation and re-election at annual general meeting of the Company pursuant to the Articles of Association. Mr. Wang will not receive any Director's emolument from the Company.

As at the Latest Practicable Date, Mr. Wang does not have any interest in the shares of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Wang has confirmed that there are no other matters relating to his re-election that need to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

**Mdm. Jiao Ruifang** (*Non-executive Director*)

Mdm. Jiao Ruifang, aged 48, was appointed as a non-executive Director and a member of the Audit Committee of the Company in January 2022. Mdm. Jiao joined the Beijing State-owned Capital Operation and Management Company Limited (“BSCOMC”) in 2014 and is currently the general manager of the capital operation department of the BSCOMC. Mdm. Jiao was appointed as a non-independent director of Beijing Foreign Enterprise Human Resources Service Co., Ltd. (北京國際人力資本集團股份有限公司) (formerly known as Beijing Urban-Rural Commercial (Group) Co., Ltd. (北京城鄉商業(集團)股份有限公司)) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600861) from June 2019 to May 2025, a director of Hainan Jingliang Holdings Co., Ltd. (海南京糧控股股份有限公司) (the shares of which are listed on Shenzhen Stock Exchange, stock codes: 000505 and 200505) from March 2022 to September 2022 and Beiqi Foton Motor Co., Ltd. (北汽福田汽車股份有限公司) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600166) from January 2022 to November 2022. Mdm. Jiao served as the board secretary of Beiren Printing Machinery Holdings Limited (北人印刷機械股份有限公司), the board secretary of Beijing Jingcheng Electric Company Limited (北京京城機電股份有限公司) and the deputy general manager of Beijing Tianhai Industrial Co., Ltd. (北京天海工業有限公司). Mdm. Jiao holds a Master of Business Administration in Finance from The Chinese University of Hong Kong-Tsinghua University.

Save as disclosed above, Mdm. Jiao (i) did not hold any directorship in other listed public companies in the last three years or any position with the Company or other members of the Group; and (ii) is and was not connected with any Directors, senior management or substantial or controlling shareholders of the Company.

There is no service contract between the Company and Mdm. Jiao for her position as a non-executive Director. She has no fixed term of service with the Company. She will be subject to retirement by rotation and re-election at annual general meeting of the Company pursuant to the Articles of Association. Mdm. Jiao will not receive any Director's emolument from the Company.

As at the Latest Practicable Date, Mdm. Jiao does not have any interest in the shares of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Mdm. Jiao has confirmed that there are no other matters relating to her re-election that need to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

**Mr. Shi Luwen** (*Independent non-executive Director*)

Mr. Shi Luwen, aged 62, has more than 38 years of experience in medical research. Since July 1987, he has been working at and is currently a professor in pharmaceutical administration and clinical pharmacy at the School of Pharmaceutical Sciences of Peking University (北京大學藥學院) (formerly known as School of Pharmaceutical Sciences of Beijing Medical University (北京醫科大學藥學院)). Since 2002, he has worked as a director at the International Research Center for Medical Administration of Peking University (北京大學醫藥管理國際研究中心), where he has been primarily involved in research and teaching. From December 2015 to December 2021, Mr. Shi served as an independent director of China Meheco Group Co., Ltd. (中國醫藥健康產業股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600056)). From May 2017 to July 2020, he served as a director of Zhejiang CONBA Pharmaceutical Co., Ltd (浙江康恩貝製藥股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600572)). Mr. Shi has served as an independent non-executive director of Hospital Corporation of China Limited (弘和仁愛醫療集團有限公司) (a company listed on the Stock Exchange (stock code: 3869)) since December 2016, an independent non-executive director of Dragon Laboratory Instruments Limited (大龍興創實驗儀器(北京)股份公司) since June 2020, an independent non-executive director of Centergate Technologies (Holding) Co., Ltd (北京中關村科技發展(控股)股份有限公司) (a company listed on the Shenzhen Stock Exchange (stock code: 000931)) since February 2022, an independent non-executive director of Shandong Boan Biotechnology Co., Ltd. (山東博安生物技術股份有限公司) (a company listed on the Stock Exchange (stock code: 6955)) since March 2022, an independent non-executive director of China National Medicines Corporation Ltd. (國藥集團藥業股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600511)) since April 2022, and an independent non-executive director of Sunho Biologics, Inc. (盛禾生物控股有限公司) (a company listed on the Stock Exchange (stock code: 2898)) since July 2023. Mr. Shi obtained his bachelor's degree in chemistry from Beijing Medical University (北京醫科大學) in July 1987. He further obtained his master's degree in education from the University of Illinois at Chicago in Illinois in July 1992. He obtained his independent director qualification from the Shanghai Stock Exchange in January 2016.

---

**APPENDIX II      DETAILS OF RETIRING DIRECTORS PROPOSED FOR RE-ELECTION**

---

Save as disclosed above, Mr. Shi (i) did not hold any directorship in other listed public companies in the last three years or any position with the Company or other members of the Group; and (ii) is and was not connected with any Directors, senior management or substantial or controlling shareholders of the Company.

There is no service contract between the Company and Mr. Shi for his position as an independent non-executive Director. He has no fixed term of service with the Company. He will be subject to retirement by rotation and re-election at annual general meeting of the Company pursuant to the Articles of Association. His emoluments comprise a Director's fee to be determined by the Board under the authority granted by the Shareholders at annual general meeting and with reference to his duties and responsibilities with the Company, the Company's performance and market situation. Mr. Shi received a Director's fee of HK\$175,000 from the Company for the year ended 31 December 2025. Save for the Director's fee, Mr. Shi did not receive any other emolument for the year ended 31 December 2025.

As at the Latest Practicable Date, Mr. Shi did not have any interest in the shares of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Shi has confirmed that there are no other matters relating to his re-election that need to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

---

## NOTICE OF ANNUAL GENERAL MEETING

---



# 華潤醫藥集團有限公司

## China Resources Pharmaceutical Group Limited

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

### NOTICE OF ANNUAL GENERAL MEETING

**NOTICE IS HEREBY GIVEN** that an annual general meeting (“AGM”) of China Resources Pharmaceutical Group Limited (the “**Company**”) will be held at 50th Floor, China Resources Building, 26 Harbour Road, Wanchai, Hong Kong on Friday, 12 June 2026 at 3:30 p.m. for the following purposes. Unless otherwise indicated, capitalized terms used herein shall have the same meanings as those defined in the circular of the Company dated 19 May 2026 (the “**Circular**”).

1. To receive and consider the audited financial statements, the directors’ report and the independent auditor’s report of the Company for the year ended 31 December 2025.
2. To declare a final dividend of RMB0.122 per share for the year ended 31 December 2025.
3.
  - (1) To re-elect Mr. Bai Xiaosong as an executive Director;
  - (2) To re-elect Mr. Cheng Jie as an executive Director;
  - (3) To re-elect Mr. Liu Changan as an executive Director;
  - (4) To re-elect Mr. Sun Yongqiang as a non-executive Director;
  - (5) To re-elect Mr. Wang Yuhang as a non-executive Director;
  - (6) To re-elect Mdm. Jiao Ruifang as a non-executive Director; and
  - (7) To re-elect Mr. Shi Luwen as an independent non-executive Director.
4. To authorise the Board to fix the remuneration of the Directors.
5. To appoint KPMG as the auditor of the Company and to authorize the Board to fix their remuneration.

---

## NOTICE OF ANNUAL GENERAL MEETING

---

6. To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

“**THAT:**

- (a) subject to paragraph (b) below, the exercise by the Directors during the Relevant Period (as hereinafter defined) of all the powers of the Company to buy back shares of the Company on the Stock Exchange or on any other stock exchange on which the securities of the Company may be listed and recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange for this purpose (and the Company may hold the shares so repurchased in treasury), subject to and in accordance with all applicable laws and the requirements of the Listing Rules or of any other stock exchange as amended from time to time, be and is hereby generally and unconditionally approved;
- (b) the total number of shares of the Company which the Directors are authorised to buy back pursuant to the approval in paragraph (a) above shall not exceed 10% of the issued shares of the Company (excluding treasury shares, if any) as at the date of this resolution, provided that if any subsequent consolidation or subdivision of shares of the Company into a different number of shares than the number of shares existing prior to such consolidation and subdivision is effected, the maximum number of shares of the Company that may be bought back under the mandate in paragraph above as a percentage of the total number of issued shares of the Company at the date immediately before and after such consolidation or subdivision shall be the same and such maximum number of shares shall be adjusted accordingly; and
- (c) for the purposes of this resolution, “**Relevant Period**” means the period from the passing of this resolution until whichever is the earliest of:
  - (i) the conclusion of the next annual general meeting of the Company;
  - (ii) the expiration of the period within which the next annual general meeting of the Company is required by law to be held; and
  - (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the Shareholders in general meeting of the Company.”

---

## NOTICE OF ANNUAL GENERAL MEETING

---

7. To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

**“THAT:**

- (a) subject to paragraph (c) below and pursuant to sections 140 and 141 of the Companies Ordinance, the exercise by the Directors during the Relevant Period (as hereinafter defined) of all the powers of the Company to allot, issue and deal with additional shares of the Company, including any sale or transfer of the treasury shares of the Company (if permitted under the Listing Rules), and to make or grant offers, agreements and options (including bonds, warrants and debentures convertible into shares of the Company) which would or might require the exercise of such power be and is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) above shall authorise the Directors during the Relevant Period (as hereinafter defined) to make or grant offers, agreements and options (including bonds, warrants and debentures convertible into shares of the Company) which would or might require the exercise of such power after the end of the Relevant Period;
- (c) the total number of shares allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) and issued by the Directors pursuant to the approval in paragraph (a) above, otherwise than (i) a Rights Issue (as hereinafter defined); (ii) an issue of shares under any option scheme or similar arrangement for the time being adopted for the grant or issue of shares or rights to acquire shares of the Company; (iii) an issue of shares upon the exercise of the subscription or conversion rights under the terms of any warrants or any securities of the Company which are convertible into shares of the Company; or (iv) an issue of shares as scrip dividends pursuant to the Articles of Association of the Company from time to time, shall not exceed 20% of the issued shares (excluding treasury shares, if any) of the Company as at the date of passing this resolution, provided that if any subsequent consolidation or subdivision of shares of the Company into a different number of shares than the number of shares existing prior to such consolidation and subdivision is effected, the maximum number of shares of the Company that may be allotted and issued under the mandate in paragraph (a) above as a percentage of the total number of issued shares of the Company at the date immediately before and after such consolidation or subdivision shall be the same and such maximum number of shares shall be adjusted accordingly; and

---

## NOTICE OF ANNUAL GENERAL MEETING

---

- (d) for the purpose of this resolution, “**Relevant Period**” means the period from the passing of this resolution until whichever is the earliest of:
- (i) the conclusion of the next annual general meeting of the Company;
  - (ii) the expiration of the period within which the next annual general meeting of the Company is required by law to be held; and
  - (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the Shareholders in general meeting of the Company; and

“**Rights Issue**” means an offer of shares open for a period fixed by the Directors to the holders of shares of the Company on the register on a fixed record date in proportion to their then holdings of such shares as at that date (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of any recognised regulatory body or any stock exchange in, any territory outside Hong Kong applicable to the Company).”

8. To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

“**THAT** subject to the passing of the resolution as proposed under items nos. 6 and 7 set out in the notice convening this AGM, the general mandate granted to the Directors to allot, issue and deal with additional shares pursuant to the resolution as proposed under item no. 7 set out in the notice convening this AGM be and is hereby extended by the addition thereto of the total number of the shares of the Company bought back by the Company under the authority granted pursuant to the resolution as proposed under item no. 6 set out in the notice convening this AGM, provided that such number of shares so bought back shall not exceed 10% of the issued shares of the Company (excluding treasury shares, if any) as at the date of the said resolution.”

By Order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Bai Xiaosong**  
*Chairman*

PRC, 19 May 2026

---

## NOTICE OF ANNUAL GENERAL MEETING

---

*Notes:*

1. Any member of the Company entitled to attend and vote at the meeting is entitled to appoint one or more proxies to attend and, on a poll, vote instead of him. A proxy need not be a member of the Company.
2. To be valid, the proxy form, together with any power of attorney or other authority (if any) under which it is signed, or a notarially certified copy thereof, must be lodged with the registered office of the Company at 41st Floor, China Resources Building, 26 Harbour Road, Wanchai, Hong Kong not less than 48 hours before the time appointed for holding the AGM or any adjournment thereof.
3. The register of members of the Company will be closed from Tuesday, 9 June 2026 to Friday, 12 June 2026, both days inclusive, during which period no transfer of shares of the Company will be effected. Shareholders whose names appear on the register of members of the Company on Friday, 12 June 2026 (record date) are entitled to attend and vote at the AGM. In order to determine the identity of members who are entitled to attend and vote at the AGM, all share transfer documents accompanied by the relevant share certificates must be lodged with the Company's Share Registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on Monday, 8 June 2026 for registration.
4. With regard to item No. 2 in this notice, the Board has recommended a final dividend of RMB0.122 per ordinary share payable on or about Monday, 3 August 2026. Subject to the approval of Shareholders at the AGM, the proposed final dividend will be payable to Shareholders whose names appear on the register of members of the Company after the close of business at 4:30 p.m. on Tuesday, 23 June 2026 and the register of members of the Company will be closed from Monday, 22 June 2026 to Tuesday, 23 June 2026, both days inclusive, during which no transfer of shares of the Company will be registered. In order to qualify for the proposed final dividend, all share transfer documents, accompanied by the relevant share certificates must be lodged with the Company's Share Registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on Thursday, 18 June 2026 for registration.
5. With regard to item No. 3 in this notice, the Board has proposed that 7 retiring Directors, namely Mr. Bai Xiaosong, Mr. Cheng Jie and Mr. Liu Changan, being eligible, shall be re-elected as executive Directors, Mr. Sun Yongqiang, Mr. Wang Yuhang and Mdm. Jiao Ruifang, being eligible, shall be re-elected as non-executive Directors, and Mr. Shi Luwen, being eligible, shall be re-elected as independent non-executive Director of the Company. Details of these Directors who offer themselves for re-election as Directors are set out in Appendix II to the Circular.
6. With regard to item No. 6 in this notice, an explanatory statement as required under the Share Buy-back Rules in connection with the Share Buy-back Proposal is set out in Appendix I to the Circular.
7. If a Typhoon Signal No. 8 or above is hoisted, or a Black Rainstorm Warning Signal or "extreme conditions after super typhoons" announced by the HKSAR Government is/are in force on the date of the Annual General Meeting, the Annual General Meeting will be considered to be postponed or adjourned. The Company will post an announcement on the Company's website ([www.crpharm.com](http://www.crpharm.com)) and the Stock Exchange's website ([www.hkexnews.hk](http://www.hkexnews.hk)) to notify Shareholders if there are any changes on the date, time and place of the Annual General Meeting.

The Annual General Meeting will be held as scheduled when an Amber or a Red Rainstorm Warning Signal is in force. Shareholders should decide on their own whether they would attend the Annual General Meeting under bad weather conditions bearing in mind their own situations.

In addition, no corporate gifts will be distributed by the Company at the above meeting.

*As at the date of this notice, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.*